Medical AI company DeepNoid has obtained medical device regulatory approval for its remote reading operation platform, marking a strategic expansion beyond AI solution supply into the medical operation platform business.
On the 6th, DeepNoid announced that its remote reading operation platform 'AxonFlow (AxonFlow)' received Class 1 software medical device approval from the Ministry of Food and Drug Safety.
AxonFlow is a platform supporting remote reading operations at hospitals and health checkup centers. It integrates all functions required for remote reading operations, including case assignment, report writing, billing, and user authentication.
The company explained that this regulatory approval lays the foundation to expand its business scope from simply supplying AI diagnostic solutions to providing services that support the entire medical institutional investor operation.
AxonFlow is designed not only to integrate with DeepNoid's proprietary medical AI but also to connect with external AI solutions. Based on this, the company plans to link reading AI with hospital operation systems and further expand into AI agent-based medical services in the future.
DeepNoid intends to further enhance AxonFlow's operation platform capabilities and develop it into a Service-as-a-Platform (SaaS) that supports various tasks of medical institutional investors by incorporating AI agents.
DeepNoid is also developing 'MedZero (MedZero)', a medical-specialized foundation model. MedZero is a multimodal AI model trained on diverse medical images such as X-rays, CT scans, and MRIs, aiming to build a medical AI model optimized for the domestic healthcare environment.
Following its recent acquisition of medical device approval for generative medical AI solution 'M4CXR' this year, DeepNoid is expanding commercialization efforts, including signing supply contracts with major domestic general hospitals. The company's strategy involves strengthening its medical AI service business by integrating AI diagnostic solutions with the AxonFlow operation platform.
Choi Woo-sik, CEO of DeepNoid, stated, "Our strategy is to transform into a medical AI service company that encompasses solutions, infrastructure, and AI agents." He added, "AxonFlow will serve as the first platform product realizing this vision, playing a key role in connecting medical institutional investor operations with AI services."
in TECH
